Back to Journals » International Journal of General Medicine » Volume 11

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

Authors Abushahin A, Janahi I, Tuffaha A

Received 4 November 2017

Accepted for publication 9 December 2017

Published 31 January 2018 Volume 2018:11 Pages 41—46

DOI https://doi.org/10.2147/IJGM.S156078

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha

Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar

Objective: The primary objective of this study was to document the hospitalization rate due to respiratory syncytial virus (RSV) and compliance with palivizumab use in preterm infants receiving palivizumab immunoprophylaxis during 2009–2012 RSV seasons.
Design: This is a descriptive single-center cohort study. Infants who were ≤35-week gestational age were eligible for enrollment if they received the first palivizumab dose between November 1 and March 31 (2009–2010, 2010–2011, 2011–2012). Primary endpoint was defined as RSV hospitalization of duration 24 hours or longer.
Results: The cumulative RSV hospitalization rate in the registry (2009–2012) was 1.9%. The compliance rate was 85.7%. It showed steady increase across the 3 successive RSV seasons, 2009–2010, 2010–2011, and 2011–2012 (57.7% vs 92.6%, 94.2%, respectively, p<0.05). The RSV hospitalization rate decreased from 3.7% for 2009–2010 to 1.3% for 2010–2011 and 1.7% for 2011–2012 RSV seasons. No deaths and no side effects linked to palivizumab injections were reported for any subjects enrolled.
Conclusion: Our study provides national data regarding characteristics, compliance rate, and hospitalization outcomes for preterm infants receiving palivizumab in Qatar. Our data is consistent with the previously reported efficacy and safety profile of palivizumab.

Keywords: palivizumab, preterm, bronchopulmonary dysplasia, bronchiolitis, passive immunization, immunoprophylaxis, RSV

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]